Enhancing health care for type 2 diabetes in Northern Brazil: A pilot study of pharmaceutical care in community pharmacy by Balisa-Rocha, Blicie Jennifer et al.
  Universidade de São Paulo
 
2012
 
Enhancing health care for type 2 diabetes in
Northern Brazil: A pilot study of
pharmaceutical care in community pharmacy
 
 
AFRICAN JOURNAL OF PHARMACY AND PHARMACOLOGY, VICTORIA ISLAND, v. 6, n. 35, supl.
1, Part 1, pp. 2584-2591, SEP, 2012
http://www.producao.usp.br/handle/BDPI/34350
 
Downloaded from: Biblioteca Digital da Produção Intelectual - BDPI, Universidade de São Paulo
Biblioteca Digital da Produção Intelectual - BDPI
Sem comunidade WoS
 African Journal of Pharmacy and Pharmacology Vol. 6(35), pp. 2584-2591, 22 September, 2012 
Available online at http://www.academicjournals.org/AJPP 
DOI: 10.5897/AJPP12.514 
ISSN 1996-0816 © 2012 Academic Journals 
 
 
 
 
Full Length Research Paper 
 
Enhancing health care for type 2 diabetes in Northern 
Brazil: A pilot study of pharmaceutical care in 
community pharmacy 
 
Blície Jennifer Balisa-Rocha1, Viviane Gibara Guimarães1, Alessandra Rezende Mesquita1, 
Patrícia Melo Aguiar2, Ines Krass3 and Divaldo Pereira de Lyra Jr.1* 
 
1Laboratory of Teaching and Research in Social Pharmacy (LEPFS), Federal University of Sergipe, Brazil. 
2Faculty of Pharmaceutical Sciences, University of São Paulo, Brazil. 
3Faculty of Pharmacy, The University of Sydney, S346, Pharmacy and Bank Building A15, NSW 2006, Australia. 
 
Accepted 10 August, 2012 
 
To evaluate the impact of a medication therapy management (MTM) program on the clinical outcomes 
and the quality of life (QoL) of a group of elderly patients with type 2 diabetes mellitus (DM). The study 
was conducted in a community pharmacy in Aracaju, Brazil, from February to November 2009. A quasi-
experimental, longitudinal, prospective study was conducted by intervention. The group patients 
received medication therapy management from a clinical pharmacist. A sample of convenience was 
obtained for patients of both genders aged from 60 to 75 years. Monthly visits were scheduled over 10 
months. At these consultations, sociodemographic, clinical data were obtained. QoL assessment was 
conducted using a generic instrument—the Medical Outcomes Studies 36-item Short Form Survey (SF-
36®). In total, 34 completed the study. The mean age of the patients was 65.9 (4.7) years. In total, 117 
DRPs were identified. Patients’ baseline and final evaluation measures for glycosylated hemoglobin, 
capillary blood glucose, blood pressure, and waist circumference were significantly different (p < 0.05). 
The domains of QoL assessed by the SF-36® also shows significant differences between patients’ 
baseline and final evaluation scores. The co-responsibility and active participation on the part of the 
elderly may have helped pharmacotherapy achieve its clinical and humanistic aims. 
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INTRODUCTION 
 
Diabetes mellitus (DM) is a chronic health condition and 
relevant risk factor to cardiovascular diseases, especially 
in elderly (Wermeille et al., 2004). In practice, the 
treatments involve counseling on behaviour change by 
family physicians and primary care teams, and referral to 
exercise specialists and registered dieticians and drug 
therapy (Assunção et al., 2002; Chatterjee et al., 2012). 
Management of elderly patients with DM is more difficult 
because of certain inherent characteristics of this age 
group, such as the presence of comorbidities, 
pathophysiological changes associated with old age, and  
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cognition loss, resulting in polypharmacy.  
Polypharmacy increase the susceptibility to adverse 
drug reactions in elderly patients and they find it difficult 
to understand the disease and its treatment (Vinks et al., 
2009; Cranor and Christensen, 2003; Paolisso, 2010). 
Taken together, these circumstances often produce poor 
control of blood glucose levels and a high incidence of 
drug-related problems (DRPs) that negatively affect the 
quality of life (QoL) of these patients (Cranor and 
Christensen, 2003; Fornos et al., 2006). Growing 
evidence demonstrates that models of diabetes care 
which involve pharmacists are able to contribute to 
improved patient outcomes (Armor et al., 2009). 
Since 1990s, pharmaceutical practice has been moving 
from a technical to a social paradigm, with services 
becoming   patient-focused  (Li,  2003).  The   practice  of  
  
 
 
 
pharmaceutical care has been defined by Hepler and 
Strand (1990) as “the responsible provision of 
pharmacotherapy, with the goal of achieving defined 
therapeutic outcomes in health and the improvement of 
quality of life of the population. In last years, 
pharmaceutical care services had a logical extension 
called medication therapy management (MTM) that is 
defined as “the optimization therapeutic outcomes 
through improved medication use” and “reduce the risk of 
adverse events, including adverse drug reactions (de 
Oliveira et al., 2010). Although there were some studies 
about MTM in Brazil, this practice is unusual in 
community pharmacies. Thus, the aim of this study was 
to develop and implement a pilot community pharmacy 
MTM program and evaluate its impact on the clinical 
outcomes and the QoL of a group of elderly patients with 
type 2 DM. 
 
 
METHODS 
 
Design and study site  
 
This study was a prospective trial pilot (single group) study 
conducted by intervention in a single community pharmacy in 
Aracaju, Brazil, from February to November 2009. Study approval 
was obtained from the Ethics Committee in Research of the 
University Hospital of the Federal University of Sergipe (Protocol n° 
0137.0.107.000-07).  
 
 
Patient selection  
 
We recruited a convenience sample through referrals of eligible 
patients from the University Hospital clinic. This comprised patients 
of both genders aged from 60 to 75 years. Included were patients 
were eligible if they had a confirmed diagnosis of type 2 DM 
according to the American Diabetes Association (ADA, 2005) and 
were taking antidiabetic medications. We excluded patients unable 
to attend scheduled visits, and patients who missed more than 3 
consecutive visits (Al Mazroui et al., 2009; Garção and Cabrita, 
2002). The target population was recruited over approximately 2 
months. All patients agreeing to participate in the study signed a 
consent form in accordance with Resolution CNS nº 196/96. 
 
 
The MTM program 
 
The MTM program comprised monthly visits scheduled over 10 
months; each lasted 40–60 min. The 9 steps of good practice of 
MTM were followed: (1) establishment of a pharmacist–patient 
therapeutic relationship; (2) collection, analysis, and interpretation 
of relevant information; (3) identification and classification of DRPs; 
(4) establishment of drug therapy goals with the patient; (5) 
determination of viable drug therapy alternatives; (6) selection of 
the best drug therapy alternative; (7) developing a plan of care; (8) 
implementation of an individual plan and monitoring of the same; 
and (9) follow-up (Hepler and Strand, 1990). For the identification of 
DRPs, the Pharmacists’ Work-Up of Drug Therapy model was used. 
This classifies DRPs into Necessity (DRPs 1 and 2), Effectiveness 
(DRPs 3 and 4), Safety (DRPs 5 and 6), and Compliance (DRPs 7) 
(Strand et al., 2004). At this stage of the process, the description of 
DRPs was based on information provided by the patients, for 
example, the problem or condition of the patient, the medication(s) 
involved, and the association of the medication(s) with the patient’s 
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problem. This identification requires clinical skills, a thorough 
knowledge of the patient as a person, as well as knowledge of the 
drug and the illness, good communication skills, and a systematic 
care process (Strand et al., 2004). 
During the MTM program, educational interventions aimed at 
personal transformation were conducted and the patient’s “critical 
awareness” was encouraged. These were inspired by the approach 
of participatory social orientation proposed by Freire (1983). 
Educational measures included oral and written instructions (with 
folders and slides). Patients were informed about DM and its 
complications; appropriate drug dosages, side effects, and 
medication storage. Changes in lifestyle particularly with regard to 
diet and physical exercise-were stressed, as was the importance of 
the management of the signs and symptoms of DM through self-
monitoring (Al Mazroui et al., 2009; American Diabetes Association, 
1996). These educational interventions were reinforced at each 
encounter with the patient. Moreover, changes in pharmacotherapy 
were discussed with the patients and physicians when necessary. 
All such changes were suggested in view of the recommendations 
of the American Diabetes Association (ADA, 2005). It is important to 
highlight that pharmacists alone could not alter pharmacotherapy: 
patients were referred to their physician for therapy adjustment. 
A detailed assessment of the pharmacotherapy was carried out 
after each interview, looking at the characteristics of each of the 
drugs in depth. This assessment was always made with regard to 
the characteristics and problems of each individual patient. 
Pharmacists assessed the safety and effectiveness of both drugs 
and lifestyle, coming to the conclusion of whether or not one or 
more DRPs had arisen or were likely to arise. Then a strategy was 
determined to solve the problem (Fornos et al., 2006). 
 
 
Data collection  
 
At each of the consultations, sociodemographic, clinical, and 
pharmacotherapeutic data were obtained. This included data on 
levels of capillary blood glucose, and blood pressure (BP), and 
measurements of Body Mass Index (BMI) and waist circumference 
(Sociedade Brasileira de Diabetes. Diretrizes da Sociedade 
Brasileira de Diabetes, 2007; Lipschitz, 1994; World Health 
Organization, 1998). Therefore, glycosylated hemoglobin (HbA1c) 
was obtained to patients at baseline (first interview) and at the end 
of the study (10-months). QoL evaluation was performed using a 
generic instrument—the Medical Outcomes Studies 36-item Short 
Form (SF-36®; Portuguese version) Ciconelli et al., (1999). This is 
was administered twice at the start and end of the 10-month period 
of the program (Freire P 1983). This instrument has 8 domains, 
which assess functional capacity, physical aspects, pain, general 
state of health, vitality, social, emotional, and mental health 
aspects. Each domain was measured on a scale of 0 to 100, with 
scores closer to 100 representing a better QoL. In this study, the 
concept of QoL was defined like a multidimensional construct, 
which comprises physical, mental, and social aspects as well as the 
perception of the general wellbeing of the individual (Hepler and 
Strand, 1990). 
 
 
Statistical analysis 
 
Data collected were double entered and then analyzed using the 
BioEstat® database (Version 5.0, National Council for Scientific and 
Technological Development [CNPq], Brazil). Statistical analyses 
were conducted: these included frequency, mean, and standard 
deviation (SD).  
Student's paired t test was used for continuous normally 
distributed variables in clinical and humanistic outcomes between 
baseline and end of study and p < 0.05 was used to indicate a 
significant    difference.  The    Cohen's   d   test   was   applied   for  
 2586          Afr. J. Pharm. Pharmacol. 
 
 
 
Patients recruited 
 (n = 50) 
1st consultation 
7 drop out 
(n = 43) 
2nd consultation 
6 drop out  
(n = 37) 
4th consultation 
1 drop out 
(n = 36) 
8th consultation 
1 drop out  
(n = 35) 
9th consultation 
1 drop out 
(n = 34) 
 
 
Figure 1. Patient abandonment 
during a community pharmacy 
study in Aracaju, Brazil, February 
to November 2009. 
 
 
 
measuring significant effect size for all variables of QoL. 
 
 
RESULTS 
 
In total, 50 patients were invited to participate in the MTM 
program pilot, and of these, 34 completed the study (drop 
out rate = 32%). The reasons reported for dropping out 
were: lack of interest (50%; n = 8), loss of 
contact(18.75%; n = 3), moving to another city (12.5%; n 
= 2), limited mobility (12.5%; n = 2), and hospitalization 
(6.25%; n = 1) (Figure 1). 
The mean patient age was 66 years, and approximately 
half were female and had not finished high school. The 
median of DM diagnosis time was 12 years. Most of 
elderly (76.5%, n = 26) were retired and had access to 
the public (44.1%, n = 15) and private (41.9%, n =14) 
health   care   service.   Their   medications   mainly  were  
 
 
 
 
Table 1. Sociodemographic characteristics of elderly 
patients (n = 34) attending at a community pharmacy 
in Aracaju, Brazil from February to November 2009. 
 
Age (years)* 65.9 (4.7) * 
Gender % (n) 
Female 52.9 (18) 
Male 47.1 (16) 
  
Marital status 
 
Married 73.5 (25) 
Single 11.7 (4) 
Divorced 8.8 (3) 
Widow 5.9 (2) 
  
Level of education 
 
Literate 5.9 (2) 
Elementary school 50.0 (17) 
High School 23.5 (8) 
College 20.6 (7) 
  
Profession 
 
Retired  76.5 (26) 
Homemaker  11.8 (n = 4) 
Employment relationship 5.9 (n = 2) 
Others 5.9 (2) 
  
Access to health service 
 
Public 44.1 (15) 
Private 41.9 (14) 
Both 14.7 (5) 
  
Diagnostic Time 13.5 (9.9)* 
Up to 10 years 35.3 (n = 12) 
10 to 20 years 35.3 (n = 12) 
>20 years 29.4 (n = 10) 
  
Risk Factors for Diabetes 
 
Hypertensiona 79.4 (n = 27) 
Family history  70.9 (n = 24) 
Increased waist circumference 58.8 (n = 20) 
Dyslipidemia 47.0 (n = 16) 
Sedentarism 47.0 (n = 16) 
Neuropathy 8.8 (n = 3) 
Nephropathy 2.9 (n = 1) 
Retinopathy 2.9 (n = 1) 
Tobacco smoking 2.9 (n = 1) 
 
* Mean (standard deviation (SD) ; a BP greater than 
140/90mmHg 
 
 
 
acquired in Farmácia Popular do Brasil for low cost. 
Regarding risk factors, a majority had family history of 
DM, hypertension and, central obesity (Table 1). 
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Table 2. Drug-related problems (DRPs) identified (n = 117) and resolved in elderly patients at a community pharmacy in 
Aracaju Brazil, according to the Pharmacist Workup Drug Therapy classification (February to November 2009). 
 
Necessities related to the medications Type of DRP 
DRP Real DRP Potential 
Total n (%) 
Identified (Resolved) Identified (Resolved) 
Indication 1 6 (5) 5 (4) 25 (21.4) 2 13 (10) 1 (1) 
     
Effectiveness 3 10 (8) 0 (0) 40 (34.2) 4 25 (24) 5 (3) 
     
Safety 5 9 (8) 5 (5) 22 (18.8) 6 6 (6) 2 (2) 
Compliance 7 25 (20) 5 (5) 30 (25.6) 
Total  94 (81) 23 (20) 117 
 
 
 
Table 3. Clinical parameters in the baseline and final evaluation of elderly patients (n = 34) at a community 
pharmacy in Aracaju Brazil, February to November 2009. 
 
Clinical parameter Baseline 
mean (SD) 
Final 
mean (SD) 
p* 
Glycosylated hemoglobin (%) 8.9 (2.1) 6.9 (0.9) < 0.001* 
Capillary glucose (mg/dL) 230.9 (103.3) 176.4 (76.5) 0.005* 
Systolic BP (mmHg) 148.5 (19.7) 128.9 (14.7) < 0.001* 
Diastolic BP (mmHg) 83.1 (12.1) 76.1 (9.8) < 0.001* 
BMI (kg.m−2) 27.9 (3.8) 28.1 (4.0) 0.089 
    
Waist measurement (cm)    
Men 98.3 (10.8) 96.6 (10.4) 0.003* 
Women 100.3 (9.4) 96.3 (13.9) 0.036* 
 
*Statistical significance: p < 0.05; BP = blood pressure; BMI = body mass index. 
 
 
 
In this study, the median of medication used was 6, and 
28 patients (82%) used 5 or more medications, resulting 
in polypharmacy. The most widely used medications 
were for the cardiovascular system (41.9%, n = 89), 
specifically inhibitors of the renin–angiotensin system 
(10.8%, n = 23) and medications which regulate the 
alimentary tract and metabolism (33.9%, n = 72). 
Medication mainly used in the treatment of DM comprised 
32% (n = 68). The most commonly used oral antidiabetics 
were metformin, and glibenclamide. 
In total, 117 DRPs were identified, with a mean of 3.4 
(1.9) DRPs per patient. The largest DRP category was 
Effectiveness (Table 2). Of the total DRPs detected, 94 
(80%) were actual and 23 (20%) potential. During patient 
follow-ups, 101 DRPs (86.3%) were resolved, with 81 
actual and 20 potential DRPs.  
A total of 500 drug therapy interventions were 
performed and documented. These included advice to 
the doctor to cease medications causing adverse 
reactions (23%), adjusting medication intervals (15%), 
explanation of the importance of improving adherence to 
treatment, (11%), request to the doctor to increase the 
dose to improve the effectiveness of pharmacotherapy 
(10%) and information to seniors on managing  self-
medication (6%). Furthermore, 48.5% of the resolved 
DRPs required decisions from physicians. Thus, a 
cooperative working relationship between the research 
pharmacist, doctors and patients were key to solving and 
preventing DRPs in pharmacy. As a result, physicians 
accepted all recommendation for changes to the 
medication regimen.  
In addition, 360 educational interventions were 
documented by the pharmacist. The most frequent were: 
advice on changes in lifestyle (14%), explanations about 
the importance of storage of medicines (12%), counseling 
on the disease (10%) and clarification of concerns about  
administration of medications (dose, time, duration of 
treatment and route of administration) (10%). 
At the end of the MTM program the patients’ mean 
HbA1c decreased 2.0%, a significant difference between 
the baseline and final evaluation (Table 3). Of these 
73.5% (n = 25) patients achieved the target HbA1c 
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Table 4. SF36® Quality of life domain scores at baseline and final evaluation for 34 elderly patients at a community 
pharmacy in Aracaju, Brazil from February to November 2009. 
 
Domain Baseline 
mean (SD) 
Final evaluation mean 
(SD) p*h 
Functional capacity 68.8 (26.2) 74.5 (23.8) 0.022* 
Physical aspects 61.7 (42.3) 78.7 (38.5) 0.003* 
Pain 57.3 (26.3) 71.3 (32.1) 0.003* 
General state of health 66.6 (17.2) 71.3 (20.1) 0.026* 
Vitality 65.0 (16.6) 76.9 (19.9) <0.001* 
Social aspects 82.7 (26.0) 86.7 (22.4) 0.235 
Emotional aspects 67.6 (42.2) 78.4 (39.2) 0.127 
Mental health 66.8 (21.6) 78.6 (18.2) <0.001* 
 
*Statistical significance: p < 0.05. 
 
 
 
of<7% (Wubben and Vivian, 2008). There were also 
significant improvements in mean capillary blood glucose 
measurements, BP (systolic and diastolic), and waist 
circumference, before and after the MTM program. It is 
noteworthy that 56% (n = 19) of the patients achieved 
capillary blood glucose control (<200 mg/dL), 62% (n = 
21) exhibited BP improvement, and 26.5% (n = 9) 
achieved waist circumference control (for men <102 cm 
and for women<88 cm) (Ferreira et al.2006; Funnell and 
Brown 2008) For BMI, a baseline of 53% (n = 18) of the 
elderly were classified as overweight and 47% (n = 16) as 
eutrophic, with no statistically significant difference (p ˂ 
0.05) at the end of the study. Changes in clinical 
parameters are shown in Table 3. 
The SF-36® scores for each domain are shown in 
Table 4. A significant difference was observed between 
the baseline and final evaluation in the domains of 
functional capacity, physical aspects, pain, general state 
of health, vitality, and mental health. For the domains of 
social and emotional aspects, mean scores increased but 
the difference was not statistically significant. Regarding 
the magnitude of the effect size showed an intermediate 
effect for domains of vitality (d = 0.6494; r = 0.3088) and 
mental health (d = 0.5908; r = 0.2833).  
 
 
DISCUSSION 
 
In Brazil, few Pharmaceutical care studies evaluated the 
improvements in clinical and humanistic outcomes. 
These studies usually were carried out with a small 
number of patients (n=30-64), on blood pressure control 
and in communities, pharmacies and ambulatories 
(Castro and Correr, 2007; Lyra et al., 2007). Then, DM 
MTM pilot program successfully implemented, 
representing an innovative approach in health care 
services delivered in community pharmacy in Brazil and 
may to be extended more broadly. 
The socio-demographic characteristics, type of access 
to health services, levels of polypharmacy, and risk 
factors presented by the elderly in this program suggest 
that the study sample was typical of an elderly population 
of type 2 diabetes patients (Wermeille et al., 2004; 
Cranor and Christensen, 2003; Al Mazroui et al., 2009; 
Castro and Correr, 2007; Cranor et al., 2003; Clifford et 
al., 2005). In this study, the proportion of patients who 
experienced some form of DRPs is similar to the findings 
of Rao et al. (2007) but is higher than values reported in 
other studies (Doucette et al., 2005; Paulino et al., 2004). 
One reason for this high rate in our study may have been 
the presence of a pharmacist qualified to identify and 
resolve DRPs (Rao et al., 2007). In this study, the mean 
DRP value per patient was close to the values found by 
Fornos et al. (2006) and Roozendaal and Krass (2009). 
These results demonstrate the high prevalence of DRPs 
in elderly patients with type 2 DM, and this emphasizes 
the need for pharmacotherapeutic follow-up of these 
patients (Zhou et al., 2009). 
Finally, the category of DRPs most commonly found in 
this study - effectiveness - corroborates data found by 
Fornos et al. (2006) but differs from most previous 
studies (Wermeille et al., 2004; Roozendaal and Krass, 
2009; Zhou et al., 2009). This discrepancy may be 
partially explained by the lack of standardization in DRP 
classification. Although the elderly patients had a mean of 
14 years of type 2 DM diagnosis, they still used mainly 
hypoglycemic first choice for the treatment of DM, such 
as metformin and glibenclamide (Sociedade Brasileira de 
Diabetes. Diretrizes da Sociedade Brasileira de Diabetes, 
2007). Probably, the clinical inertia has been one of the 
factors that influenced in a greater frequency of DRPs 
effectiveness. 
The positive impact of pharmaceutical interventions on 
the values of most of the clinical variables was an 
important result of this study. For HbA1c, the reduction of 
2.0% was higher than that seen in other recent research 
and the same is true for reductions in BP and capillary 
blood glucose seen in this study (Wermeille et al., 2004; 
Fornos et al., 2006; Al Mazroui et al., 2009; Clifford et al., 
2005). 
  
 
 
 
Furthermore, the large proportion of patients who 
achieved    the   clinical    goals   for   DM   shows     that 
pharmaceutical interventions can provide clinically 
relevant differences for these patients (American 
Diabetes Association, 2005). According to the UK 
Prospective Diabetes Study (1998), a reduction of at 
least 0.5% in HbA1c levels leads to an estimated 18.5% 
reduction in microvascular complications and a 10.5% 
lowering of DM-related mortality. Regarding BP, the 
difference of 10/5 mmHg seen in the present study would 
lead to a reduction of 44% in the risk of stroke, a 37% 
lowering of the risk of microvascular complications, and a 
32% reduction in DM-related mortality (UK Prospective 
Diabetes Study Group, 1998). 
In the present study, BMI was the only clinical variable 
which showed no significant difference before and after 
intervention. This may be because lack of power this pilot 
study and compared to younger patients, the elderly are 
less likely or less capable of performing physical activities 
that minimize weight gain (Abbatecola et al., 2008). It is 
also worth highlighting other healthcare professionals 
such as doctors, nutritionists, and physical trainers are 
needed to support lifestyle change in elderly patients 
(Ahrens et al., 2003; Guimarães and Ciolac, 2004). 
Although there was reduction in the clinical parameter 
of waist circumference, measurements did not reach the 
cutoff recommended by the World Health Organization 
(WHO, 1998). However, while waist circumference is one 
of the most widely used indicators for measuring the 
centralized distribution of adipose tissue in individual and 
collective assessments (WHO, 1995) differences in body 
composition between different age and racial groups 
hinder the development of universal cutoff points 
(Ferreira et al., 2006). 
In this study, the inclusion of educational interventions 
was considered fundamental to the success of the MTM 
program. As part of this approach, it was important for the 
elderly to assume an active role in their educational 
development. Similar findings were reported in a recent 
systematic review of 4 studies; the review showed a 
significant improvement in pharmacotherapeutic 
outcomes amongst elderly patients who used an 
individualized education provided by a pharmacist 
(George et al., 2008). According to the National 
Standards for Diabetes Self-Management Education 
(2008) (Funnell and Brown, 2008) there are basic guiding 
principles for the development of these interventions, and 
this resource also discusses the need for continued 
support to sustain the progress made by participants of 
educational programs, stating that education about DM is 
effective in improving both patients’ clinical outcomes and 
QoL.  
In this study, improvements in patient QoL scores were 
probably the result of the effectiveness of educational 
interventions, and of greater patient contact with their 
clinical pharmacists. The results from the SF-36 analysis 
are similar to those found by Elnour et al.  (2008)  and  Al  
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Mazrouiu et al. (2009). These data also support the use 
of this generic QoL instrument for the evaluation of the 
impact of education programs for DM patients (Brown et 
al., 2000). For the social aspects and emotional aspects 
domains, improvement was observed, but the differences 
were not statistically significant. In the case of social 
aspects it was noted that there were high baseline 
scores, reflecting a possible ceiling effect in this domain. 
Polypharmacy, a characteristic of the sample studied, 
may have contributed to the lack of positive impact on the 
emotional aspects domain scores (Lyra et al., 2007). The 
results of effect size (Cohen's d) and the improvement of 
the physical aspect, pain, vitality and mental state of 
patients suggest that the changes associated with the 
program have put to practical significance. Despite the 
results show the improvement in functional capacity and 
general health status of patients, we could not prove the 
influence of the program due to the small magnitude of 
size effect. 
 
 
Limitations 
 
In this study, the dropout rate was relatively high. 
However, the reported reasons for this were consistent 
with other studies (Garção and Cabrita, 2002; Lee et al., 
2006). According to Martinez-Perez (2004) the 
abandonment of monitoring programs reflects poor 
patient knowledge about their illness. In this study, elderly 
patients’ lack of experience in receiving care from 
pharmacists could have been the main reason for their 
drop out of the service. MTM program abandonment 
rates and their causes are important indicators and need 
to be taken into account when developing appropriate 
strategies for the design of the studies in this area.  
In this pilot, 10 months was considered an adequate 
evaluation period. However, since pilot studies like this 
one cannot be used for more than hypothesis gene-
ration, new long-term studies are now necessary to 
validate the clinical and humanistic benefits 
demonstrated in this study. The limitations of a pilot 
program (1 research site and the small sample size) 
should be considered when developing future studies; 
more patients and pharmacies are needed. Moreover, the 
inclusion of a control group and the evaluation of the 
economic impact of this service should be included in 
future research to increase the robustness and reliability 
of the results. 
Regarding QoL assessment, although the SF-36 has 
been frequently used in MTM research, several studies 
have criticized the lack of specificity and sensitivity of this 
instrument for this function (Billups et al., 2000; Malone et 
al., 2001; Kheir et al., 2004). Thus the develop-ment of 
an instrument designed to specifically measure the 
impact on QoL as a result of MTM services could 
optimize the detection and evaluation of positive results 
from  this  program  (Schultz,  2001;  Pickard  and   Hung,  
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2006). 
 
 
Conclusion 
 
This pilot study at a community pharmacy in Brazil 
demonstrated that MTM interventions coupled with an 
educational program led to improvements QoL scores 
and clinical parameters for a group of elderly patients. 
From the results obtained it could be suggested that 
community pharmacists may play a valuable role in 
health care provide to patients with type 2 diabetes by 
focusing on optimizing the benefits of pharmacotherapy.  
Future studies are needed for to enhance the 
methodology used, including the following: evaluation of 
MTM structure and process; construction, validation and 
standardization of research tools; correct randomization; 
description of the sample size; impact of educational 
interventions; and evaluation of economic results. 
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